Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate
Standard BioTools Q1 2024 GAAP EPS $(0.27) Misses $(0.12) Estimate, Sales $45.540M Miss $46.006M Estimate
Standard BioTools 2024年第一季度GAAP每股收益（0.27）未達到預期（0.12）美元，銷售額爲4554萬美元，低於4,6006萬美元的預期
Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.12) by 125 percent. This is a 28.57 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $45.540 million which missed the analyst consensus estimate of $46.006 million by 1.01 percent. This is a 81.30 percent increase over sales of $25.119 million the same period last year.
標準生物工具（納斯達克股票代碼：LAB）公佈的季度虧損爲每股0.27美元，比分析師普遍預期的0.12美元（0.12美元）低125％。這比去年同期每股虧損0.21美元（0.21美元）下降了28.57％。該公司公佈的季度銷售額爲4,554萬美元，比分析師普遍預期的4,6006萬美元低1.01％。這比去年同期的251.19億美元的銷售額增長了81.30％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。